High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action

Ann Surg. 2022 Dec 1;276(6):1023-1028. doi: 10.1097/SLA.0000000000004682. Epub 2020 Dec 22.

Abstract

Objective: To identify rates of positive circumferential resection margin (CRM) for colon cancer surgery in the US.

Summary background data: CRM is one of the most important determinants of local control in colorectal cancers. The extent to which CRM involvement exists after colon cancer surgery is unknown.

Methods: Colon cancer cases with resection 2010 to 2015 were identified from the National Cancer Data Base. Adjusting for patient and tumor characteristics, comparisons were made between cases with CRM > 1 mm (negative margin) and those with margin involved with tumor or ≤ 1 mm (positive margin, CRM+). Hospital-level analysis was performed, examining observed-to-expected CRM+ rates.

Results: In total, 170,022 cases were identified: 150,291 CRM- and 19,731 CRM+ (11.6%). Pathologic T-category was the greatest predictor of CRM+, with higher rates in pT4(25.8%), pT4A(24.7%), and pT4B(31.5%) versus pT1(4.5%), pT2(6.3%) and pT3 (10.9%, P < 0.001). Within pT4 patients, predictors of CRM+ included signet-ring histology (38.1% vs 26.7% nonmucinous, and 26.9% mucinous adenocarcinoma, P < 0.001), removing < 12 lymph nodes (36.5% vs 26.1% >12, P < 0.001), community facilities (32.7%) versus academic/research (23.6%, P < 0.001), year (30.1% 2010 vs 22.6% 2015, P < 0.001), and hospital volume (24.5% highest quartile vs 32.7% lowest, P < 0.001). Across 1288 hospitals, observed-to-expected ratios for CRM+ ranged from 0 to 7.899; 429 facilities had higher than expected rates.

Conclusions: Overall rate of CRM+ in US colon cancer cases is high. Variation exists across hospitals, with higher than expected rates in many facilities. Although biology is a major influencing factor, CRM+ rates represent an area for multidisciplinary improvement in quality of colon cancer care.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / surgery
  • Adenocarcinoma, Mucinous* / pathology
  • Colonic Neoplasms* / pathology
  • Colonic Neoplasms* / surgery
  • Digestive System Surgical Procedures*
  • Humans
  • Margins of Excision
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Rectal Neoplasms* / surgery
  • Retrospective Studies